ImmunityBio

#4224

Rank

$2.42B

Marketcap

United States

Country

Leadership team

Dr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc. (Exec. Chairman, Global Chief Scientific & Medical Officer)

Mr. Richard Gerald Adcock (Pres, CEO & Director)

Mr. David C. Sachs (CFO, Principal Financial Officer & Principal Accounting Officer)

Products/ Services

Health Care, Health Diagnostics, Therapeutics

Number of Employees

500 - 1000

Headquarters

Culver City, California, United States

Established

2014

Company Registration

SEC CIK number: 0001326110

Revenue

500K - 2M

Traded as

IBRX

Social Media

URL

https://immunitybio.com

Overview

Location

Recognition and Award

References

Summary

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

History

In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials. The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."

Clinical trials

ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa.

Mission

Our mission is to apply the latest technology and clinical data to develop novel treatments for cancer through immunotherapy, empowering patients to reclaim control of their lives with safe, effective and affordable therapies.

Vision

Our vision is to create a world where no cancer patient needs to suffer, where cancer prevention and treatment are accessible to all, and where patients are empowered to make informed decisions about their health.

Key Team

Dr. Leonard S. Sender M.D. (Chief Operating Officer)

Mr. Jason R. Liljestrom (Gen. Counsel & Corp. Sec.)

Ms. Sarah Singleton (Chief Communications Officer)

Dr. Sandeep K. Reddy M.D. (Chief Medical Officer)

Dr. Barry J. Simon M.D. (Chief Corp. Affairs Officer & Director)

Dr. Hans Georg Klingemann M.D., Ph.D. (Chief Science Officer of Cellular)

Ms. Helen Luu (Chief Commercial Officer)

Recognition and Awards

ImmunityBio was selected as one of the CNBC Upstart 100 in 2020, recognizing our innovative approach to fighting cancer. We have also been named one of Fast Company’s Most Innovative Companies in 2019, as well as one of Inc.’s Best Workplaces in 2018.